In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
复制标题
KHT 肉瘤对放射增敏剂和 BCNU 联合化疗的体内反应。
DOI：
10.1038/bjc.1981.13
复制
发表时间：
1981
影响因子：
8.8
通讯作者：
Sutherland,RM
中科院分区：
文献类型：
--
作者：
Mulcahy,RT;Siemann,DW;Sutherland,RM
用1，3-二(2-氯乙基)-1-亚硝脲(BCNU，30 mg/kg，ip)或与其脱甲基化代谢物Ro-05-9963(2.0 mg/g，ip)合用。通过肿瘤生长延迟试验(即测量肿瘤生长到治疗大小所需的中位数时间x 4)来评估药物治疗的有效性。并评价硝基咪唑类药物在给药前12h至给药后12h内不同给药方案的相对疗效。未经治疗的对照组KHT肿瘤在4天的中位时间内生长到初始大小x 4。单独使用硝基咪唑的小鼠没有明显的生长延迟，而单独使用BCNU的小鼠的生长平均延迟了7天。BCNU后3h给予9963联合化疗可明显延长肿瘤生长的中位时间至9d。然而，在这些药物的任何其他组合中，没有产生显著的生长延迟。MISO在BCNU前3h给药的中位生长延迟缩短到5d，而在BCNU后3h、6h和12h同时给予MISO则显著增加生长延迟(9d)。这些结果表明，MISO和0063都可以与传统的治疗药物相结合，在这种情况下是亚硝脲，以产生增强的肿瘤反应。这种反应的产生似乎是与硝基咪唑和时间表有关的。
Female C3H/HeJ mice bearing intramuscularly transplanted KHT sarcomas were treated with a single dose of 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU, 30 mg/kg, ip) alone or in combination with a single dose of misonidazole (MISO, 1.0 mg/g, ip) or its desmethylated metabolite Ro-05-9963 (2.0 mg/g, ip). The effectiveness of drug therapy was assessed by a tumour growth-delay assay (ie measuring the median time required for tumours to grow to treatment size x 4). The relative efficacy of administering the nitroimidazoles in various schedules ranging from 12 h before to 12 h after BCNU administration also was evaluated. Untreated control KHT tumours grew to the initial size x 4 in a median time of 4 days. No significant growth delay was seen in mice treated with either nitroimidazole alone, whilst treatment with BCNU alone produced a median growth delay of 7 days. Combination chemotherapy with 9963 administration 3 h after BCNU significantly increased the median tumour growth delay to 9 days. However, no significant growth delay was produced in any of the other combinations of these agents. The median growth delay was significantly reduced to 5 days when MISO was administered 3 h before BCNU, whereas MISO administered simultaneously 3, 6, or 12 h after BCNU significantly enhanced delays (9 days). These results indicate that both MISO and 0063 may be combined with conventional therapeutic agents, in this particular case a nitrosourea, to produce an enhanced tumour response. The production of such a response appears to be nitroimidazole as well as schedule dependent.
登录
查看更多内容
%20重要性%20of%20the%20照射前%20呼吸%20次%20of%20氧气%20和%20碳素%20(5%%20CO2:%2095%%20O2)%20on%20the%20in%20vivo%20辐射%20反应%
DOI：
--
发表时间：
1977
期刊：
International Journal of Radiation Oncology, Biology, Physics
影响因子：
--
作者：
Dietmar W. Siemann;R. Hill;Raymond S. Bush
通讯作者：
Raymond S. Bush
高温对缺氧细胞放射增敏剂 Ro-07-0582 对体外哺乳动物细胞的差异细胞毒性的影响。
影响因子：
8.8
作者：
I. Stratford;G. Adams
通讯作者：
G. Adams
2-硝基咪唑 Ro-07-0582 在缺氧乳腺细胞中的放射增敏和毒性作用。
影响因子：
3.4
作者：
B. Moore;B. Palcic;L. Skarsgard
通讯作者：
L. Skarsgard
两种硝基咪唑放射增敏剂在体外肿瘤模型中的细胞毒性。
DOI：
--
发表时间：
1976
期刊：
International Journal of Radiation Oncology, Biology, Physics
影响因子：
--
作者：
R. Sridhar;C. Koch;R. Sutherland
通讯作者：
R. Sutherland
缺氧细胞放射增敏剂 Ro 7-0582 对体内肿瘤细胞的细胞毒性作用。
影响因子：
3.4
作者：
J. Brown
通讯作者：
J. Brown